Why Menopause & MHT Clinical Navigator?
The “Timing Hypothesis” Operationalized
Translates The Menopause Society (NAMS) and ACOG guidelines into algorithmic bedside decision points, stratifying the favorable therapeutic window (<60 years of age and/or <10 years from the Final Menstrual Period) to maximize cardiovasculo-protective benefits while minimizing thrombotic and vascular risks.
Endometrial Guard & Route Optimization Engine
Prevents unopposed estrogen complications by enforcing mandatory progestogen pairing (oral micronized progesterone or 52 mg LNG-IUD) for patients with an intact uterus, while automatically shifting to transdermal 17β-estradiol routes when baseline metabolic, hypertriglyceridemic, or thrombotic risk factors are flagged.
Safety Triage & Point-of-Care EHR Synthesis
Screens for absolute contraindications—including active liver disease, unexplained vaginal bleeding, history of breast cancer, and active VTE—while compiling fully formatted, documentation-ready EHR consultation notes with tailored patient education handouts.
Clinical Workflow: 5-Module Architecture
Module 1: Patient Staging & “Timing Hypothesis” Triage
- Chronologic Age & FMP Timeline: Calculates elapsed time since Final Menstrual Period (FMP) to categorize the window of opportunity (Favorable Window <10y / <60yo vs. Caution 10–14y vs. Elevated Risk ≥10–15y).
- Uterine Anatomy & Surgical Status: Captures intact uterus versus post-hysterectomy anatomy to establish mandatory progestogen pairing versus estrogen monotherapy (ET).
- Core Symptom Inventory: Catalogs vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), sleep architecture disruption, affective lability, and bone loss/fracture risk (DXA/FRAX).
- Clinical Vignette Presets: Rapidly loads calibrated clinical scenarios (e.g., Standard Window, Metabolic Risk Profile, Post-Hysterectomy ET, Prior VTE Contraindication, Late Presentation).
Module 2: Contraindications & Vascular Safety Screen
- Absolute Contraindication Guardrails: Screens for active thromboembolic disease, estrogen-dependent malignancies (breast/endometrial), unexplained uterine bleeding, and acute liver failure.
- Cardiometabolic Risk Profiling: Evaluates hypertension, hypertriglyceridemia (>200–400 mg/dL), elevated BMI, and tobacco consumption.
- Route Mandates: Flags clinical indications where transdermal estradiol is non-negotiable to bypass first-pass hepatic conversion and avoid increasing sex hormone-binding globulin (SHBG) or clotting factors.
Module 3: Regimen Builder & Endometrial Protection
- Estrogen Formulation & Titration: Calibrates low-, standard-, and ultra-low-dose transdermal patches, topical gels, and oral 17β-estradiol formulations.
- Progestogen Selection: Enforces evidence-based endometrial protection protocols utilizing micronized progesterone (100 mg continuous nightly or 200 mg sequential) or the 52 mg levonorgestrel-releasing IUD.
- Local Vaginal Estrogen Protocols: Delineates non-systemic, ultra-low-dose vaginal rings, inserts, and creams for isolated GSM without requiring systemic progestogen opposition.
Module 4: Real-Time Decision Support HUD
- Persistent Clinical Status: Real-time HUD actively reflects the Timing Window status, systemic MHT eligibility, mandated route of delivery, and endometrial safety requirements.
- Biological Rationale Explanations: Displays underlying mechanistic pearls (e.g., vascular endothelial estrogen receptor alpha integrity, hepatic clotting factor synthesis, and GABAergic sleep modulation).
Module 5: EHR Documentation & Clinical Pearls
- Automated Consultation Documentation: Compiles a structured, copy-ready clinical note (.MHTNOTE) detailing eligibility, baseline staging, regimen rationale, and surveillance timelines.
- Patient-Facing Instructions & PDF Export: Generates clean, printable clinical summaries and counseling pearls covering administration schedules, expected bleeding profiles, and warning signs.
- Evidence References: Direct integration with The Menopause Society 2022/2023 position statements and WHI long-term cumulative follow-up trial data.
How to Use the Menopause & MHT Clinical Navigator in Practice
- Input Patient Age, FMP & Anatomy: Enter current chronologic age, years elapsed since the Final Menstrual Period, and uterine anatomy (intact uterus vs. prior hysterectomy) to evaluate the “Timing Hypothesis” window.
- Check Presenting Indications: Select the patient’s dominant symptoms across vasomotor flushes, genitourinary atrophy (GSM), sleep disturbance, mood changes, and osteoporotic fracture risk.
- Complete the Safety & Metabolic Screen: Audit for absolute contraindications and review cardiometabolic risk factors (tobacco use, BMI, hypertension, triglycerides) to identify candidates requiring transdermal delivery.
- Formulate & Verify Regimen: Select the systemic or local therapy, verifying that an opposing progestogen (such as oral micronized progesterone 100 mg) is co-prescribed whenever a uterus is present.
- Review HUD & Export Clinical Note: Verify parameters on the Clinical Decision Support HUD, export the structured consultation note into your EHR chart, and provide the tailored patient education handout.
